Company news

Nxera Pharma Co., Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025

August 8, 2025

Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management

August 5, 2025

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

July 4, 2025

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568

June 2, 2025

Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

June 1, 2025

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025

May 2, 2025

Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

April 30, 2025

Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations

April 30, 2025

← Newer news releases

Calls

The 5 newest of 9 calls. Every call is listed under its year.

Decks

The 5 newest of 83 decks. Every deck is listed under its year.